Innovative Small-Cap Biopharma Companies Lead the Future of Pain Therapy

The global transdermal patch market, valued at $7.8 billion in 2023, is projected to reach nearly $10.95 billion by 2030, with pain patches leading the growth from $4.8 billion in 2021 to $7.3 billion by 2031. This growth is not just about convenience but also addresses critical issues like managing chronic pain in aging populations and providing needle-free medication delivery, offering a safer alternative to traditional opioid use.

Nutriband Inc. (NASDAQ: NTRB) is making strides in the opioid pain management space with its AVERSA Fentanyl, a transdermal patch designed to deter abuse, misuse, and accidental exposure. The company's proprietary AVERSA technology and its revenue-generating subsidiary, Pocono Pharma, position it as a unique player in the sector. Collegium Pharmaceutical, Inc. (Nasdaq: COLL) is emerging as a standout in the pain and neuropsychiatry treatment markets, with consistent revenue growth and a diversified product portfolio. Assertio Holdings, Inc. (Nasdaq: ASRT) is transitioning into a specialty pharmaceutical company, focusing on high-potential assets and reducing legal exposure. Aquestive Therapeutics, Inc. (Nasdaq: AQST) is advancing innovative, non-invasive treatments for severe allergic reactions, with a late-stage proprietary candidate, Anaphylm™, nearing regulatory approval.

These companies represent the forefront of innovation in pain therapy and drug delivery, addressing significant public health challenges and offering promising investment opportunities in the biopharma sector.